Followers | 2540 |
Posts | 250759 |
Boards Moderated | 35 |
Alias Born | 05/06/2014 |
Thursday, February 04, 2016 1:23:56 AM
$LIXT recent news/filings
## source: finance.yahoo.com
Wed, 03 Feb 2016 21:40:17 GMT ~ LIXTE BIOTECHNOLOGY HOLDINGS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
read full: http://biz.yahoo.com/e/160203/lixt8-k.html
*********************************************************
Wed, 03 Feb 2016 15:00:00 GMT ~ Lixte Biotechnology Holdings, Inc.'s Lead Compound LB-100 Reported to Rapidly Improve Symptoms in a Rodent Model of Depression
[Marketwired] - Lixte Biotechnology Holdings, Inc. announced that neuroscientists at the French Institute of Health and Medical Research using a mouse model of depression have identified protein phosphatase 2A as a potential ...
read full: http://finance.yahoo.com/news/lixte-biotechnology-holdings-inc-lead-150000942.html
*********************************************************
Tue, 26 Jan 2016 11:02:52 GMT ~ LIXTE BIOTECHNOLOGY HOLDINGS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale
read full: http://biz.yahoo.com/e/160126/lixt8-k.html
*********************************************************
Mon, 25 Jan 2016 15:30:00 GMT ~ Lixte Completes Private Placement of Convertible Preferred Stock
[Marketwired] - Lixte Biotechnology Holdings, Inc. announced today that a major shareholder has purchased $1,750,000 of Convertible Preferred stock. If fully converted, this purchase would convert to 2,187,500 common ...
read full: http://finance.yahoo.com/news/lixte-completes-private-placement-convertible-153000380.html
*********************************************************
Tue, 05 Jan 2016 01:05:00 GMT ~ Lixte Biotechnology Holdings, Inc. Announces Exclusive Licensing Of Their Lead Anti-Cancer Compound LB-100 For Potential Treatment Of Hepatocellular Carcinoma In Asia To Taipei Medical University
[PR Newswire] - EAST SETAUKET, N.Y., Jan. 5, 2016 /PRNewswire/ -- Lixte Biotechnology Holdings, Inc. (LIXT) announced last week that it has granted an exclusive license of its lead anti-cancer compound, LB-100, for treatment of hepatocellular carcinoma (HCC) in Asia to Taipei Medical University (TMU). Under the license, Taipei Medical University will determine the effectiveness of LB-100 against HCC in clinical trials conducted in compliance with both Taiwanese and American regulatory requirements. TMU will pay milestone and royalty payments to Lixte. Both parties recognize that development of improved therapy for HCC has been very challenging and that success cannot be guaranteed.
read full: http://finance.yahoo.com/news/lixte-biotechnology-holdings-inc-announces-010500168.html
*********************************************************
$LIXT charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$LIXT company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/LIXT/company-info
Ticker: $LIXT
OTC Market Place: OTCQB
CIK code: 0001335105
Company name: Lixte Biotechnology Holdings, Inc.
Company website: http://www.lixte.com
Incorporated In: DE, USA
Business Description: Lixte Biotechnology Holdings, Inc. is a clinical-stage public pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. Lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. The current drug portfolio includes inhibitors of protein phosphatases that are critical to cell division and DNA damage repair and inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation.Less >>
$LIXT share structure
## source: otcmarkets.com
Market Value: $11,968,954 a/o Feb 03, 2016
Shares Outstanding: 47,875,814 a/o Nov 03, 2015
Float: Not Available
Authorized Shares: 100,000,000 a/o Dec 30, 2014
Par Value: 0.001
$LIXT extra dd links
Company name: Lixte Biotechnology Holdings, Inc.
Company website: http://www.lixte.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=LIXT+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=LIXT+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=LIXT+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/LIXT/news - http://finance.yahoo.com/q/h?s=LIXT+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/LIXT/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/LIXT/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=LIXT+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/LIXT
DTCC (dtcc.com): http://search2.dtcc.com/?q=Lixte+Biotechnology+Holdings%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Lixte+Biotechnology+Holdings%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Lixte+Biotechnology+Holdings%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.lixte.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.lixte.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.lixte.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/LIXT
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001335105&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/LIXT/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/LIXT/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=LIXT&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=LIXT
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/LIXT/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=LIXT+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=LIXT+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=LIXT
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=LIXT
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=LIXT+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/LIXT/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=LIXT+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/LIXT.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=LIXT
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/LIXT/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/LIXT
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/LIXT
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/LIXT:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=LIXT
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=LIXT
Recent LIXT News
- LIXTE Receives U.S. Patent Issue Notification for Immune Oncology • GlobeNewswire Inc. • 09/04/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/26/2024 08:05:14 PM
- First Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company • GlobeNewswire Inc. • 08/26/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/23/2024 08:05:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/19/2024 09:17:22 PM
- LIXTE Biotechnology Provides Update On Recent Activities and Developments • GlobeNewswire Inc. • 08/19/2024 12:30:00 PM
- LIXTE Biotechnology Holdings to Present at Two Investor Conferences • GlobeNewswire Inc. • 08/15/2024 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:06:29 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:05:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/12/2024 08:05:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2024 05:55:35 PM
- LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial • GlobeNewswire Inc. • 06/14/2024 03:00:00 PM
- LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial • GlobeNewswire Inc. • 06/14/2024 01:30:00 PM
- Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System • GlobeNewswire Inc. • 06/06/2024 12:30:00 PM
- LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer • GlobeNewswire Inc. • 06/03/2024 12:30:00 PM
- LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer” • GlobeNewswire Inc. • 05/08/2024 01:25:00 PM
- Mixed Shelf Filing Gives Micro Cap Delayed Boost • AllPennyStocks.com • 04/24/2024 07:25:00 PM
- Biotech Steals The Show Following Pre-Clinical Data Announcement • AllPennyStocks.com • 03/27/2024 07:35:00 PM
- NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES • GlobeNewswire Inc. • 03/27/2024 12:30:00 PM
- LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments • GlobeNewswire Inc. • 03/21/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 09:59:41 PM
- Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research • GlobeNewswire Inc. • 02/27/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 03:48:13 PM
- LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI • GlobeNewswire Inc. • 02/26/2024 01:30:00 PM
- First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial • GlobeNewswire Inc. • 01/29/2024 01:30:00 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM